
0.3321 Delayed Data As of May 20 | ![]() Today’s Change | 0.31 Today|||52-Week Range 4.33 | -85.31% Year-to-Date |
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates May 09 / Zacks.com - Paid Partner Content |
Previous close | 0.35 |
Today’s open | 0.36 |
Day’s range | 0.31 - 0.37 |
Volume | 11,523,171 |
Average volume (3 months) | 8,648,116 |
Market cap | $60.1M |
Earnings growth (last year) | +38.46% |
Earnings growth (this year) | +51.43% |
Earnings growth (next 5 years) | +15.80% |
Revenue growth (last year) | -27.68% |
P/E ratio | NM |
Price/Sales | 1.76 |
Price/Book | 0.76 |
Today’s change | Today’s % change | |
---|---|---|
BLRXBioLine RX Ltd | -0.02 | -1.93% |
ORTXOrchard Therapeutics... | -0.01 | -2.04% |
ADMPAdamis Pharmaceutica... | -0.03 | -7.73% |
--Herantis Pharma Oyj | 0.00 | 0.00% |
Next reporting date | August 10, 2022 |
EPS forecast (this quarter) | -$0.28 |
Annual revenue (last year) | $213.6M |
Annual profit (last year) | -$282.8M |
Net profit margin | -132.43% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |